###begin article-title 0
###xml 47 61 <span type="species:ncbi:10245">vaccinia virus</span>
###xml 97 102 <span type="species:ncbi:10090">mouse</span>
Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum
###end article-title 0
###begin p 1
Y. Tomimori, K. Yumoto, and S. Hasegawa contributed equally to this paper.
###end p 1
###begin p 2
K. Yumoto's present address is NASA Ames Research Center, Moffett Field, CA 94035.
###end p 2
###begin p 3
###xml 127 135 <span type="species:ncbi:10255">smallpox</span>
###xml 190 198 <span type="species:ncbi:10255">smallpox</span>
###xml 284 298 <span type="species:ncbi:10245">vaccinia virus</span>
###xml 300 304 <span type="species:ncbi:10245">VACV</span>
###xml 393 401 <span type="species:ncbi:9606">patients</span>
###xml 405 409 <span type="species:ncbi:10245">VACV</span>
###xml 436 441 <span type="species:ncbi:10090">mouse</span>
###xml 581 585 <span type="species:ncbi:10090">mice</span>
###xml 598 602 <span type="species:ncbi:10090">mice</span>
###xml 763 767 <span type="species:ncbi:10245">VACV</span>
###xml 934 938 <span type="species:ncbi:10090">mice</span>
###xml 1049 1057 <span type="species:ncbi:9606">patients</span>
###xml 1135 1143 <span type="species:ncbi:9606">patients</span>
Threats of bioterrorism have renewed efforts to better understand poxvirus pathogenesis and to develop a safer vaccine against smallpox. Individuals with atopic dermatitis are excluded from smallpox vaccination because of their propensity to develop eczema vaccinatum, a disseminated vaccinia virus (VACV) infection. To study the underlying mechanism of the vulnerability of atopic dermatitis patients to VACV infection, we developed a mouse model of eczema vaccinatum. Virus infection of eczematous skin induced severe primary erosive skin lesions, but not in the skin of healthy mice. Eczematous mice exhibited lower natural killer (NK) cell activity but similar cytotoxic T lymphocyte activity and humoral immune responses. The role of NK cells in controlling VACV-induced skin lesions was demonstrated by experiments depleting or transferring NK cells. The proinflammatory cytokine interleukin (IL)-17 reduced NK cell activity in mice with preexisting dermatitis. Given low NK cell activities and increased IL-17 expression in atopic dermatitis patients, these results can explain the increased susceptibility of atopic dermatitis patients to eczema vaccinatum.
###end p 3
###begin p 4
###xml 730 731 730 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">1</xref>
###xml 901 902 901 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">2</xref>
###xml 4 12 <span type="species:ncbi:10255">smallpox</span>
###xml 38 52 <span type="species:ncbi:10245">vaccinia virus</span>
###xml 54 58 <span type="species:ncbi:10245">VACV</span>
###xml 191 196 <span type="species:ncbi:9606">human</span>
###xml 227 235 <span type="species:ncbi:10255">smallpox</span>
###xml 458 466 <span type="species:ncbi:10255">smallpox</span>
###xml 529 535 <span type="species:ncbi:9606">people</span>
###xml 554 562 <span type="species:ncbi:10255">smallpox</span>
###xml 787 795 <span type="species:ncbi:10255">smallpox</span>
The smallpox vaccine consists of live vaccinia virus (VACV) and is considered the gold standard of vaccines, as it has led to the complete eradication of a lethal infectious disease from the human population. Recent fears that smallpox might be deliberately released in an act of bioterrorism have led to renewed efforts to better understand the disease mechanism and to develop a safer vaccine. Approximately 50% of US residents were born after the regular smallpox vaccination was discontinued in 1972. Thus, these unimmunized people are vulnerable to smallpox. The population landscape is very different between now and 36 yr ago, with two-to-three times more frequent incidence of atopic dermatitis in the current population (1). Individuals with atopic dermatitis are excluded from smallpox vaccination because of their propensity to develop eczema vaccinatum, a disseminated vaccinia infection (2).
###end p 4
###begin p 5
###xml 58 59 58 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">3</xref>
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 666 667 666 667 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 793 794 793 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 796 797 796 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 877 878 877 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 910 911 910 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 1015 1016 1015 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 904 908 <span type="species:ncbi:10245">VACV</span>
###xml 957 965 <span type="species:ncbi:9606">patients</span>
Atopic dermatitis is a chronic inflammatory skin disease (3). The etiology of this disease is multifactorial, and involves complex interactions between genetic and environmental factors. The skin in a preatopic dermatitis state has been postulated to have hypersensitivity to environmental triggers, resulting from a defective skin barrier that allows the penetration of allergens and microbial pathogens (4). The acute phase is characterized by eczematous skin lesions with an infiltration of Th2 cells. The chronic phase is characterized by lichenification of skin and an infiltration of Th1 cells. As recent studies have established IL-17- and IL-22-producing CD4+ T cells as a distinct class of helper T cells (Th17), Th17 cells are also implicated in the acute but not the chronic phase (5, 6). Despite the progress in our understanding of atopic dermatitis pathogenesis (7) and immune responses to VACV (8), it is not understood why atopic dermatitis patients are susceptible to developing eczema vaccinatum (9).
###end p 5
###begin p 6
###xml 37 42 <span type="species:ncbi:10090">mouse</span>
###xml 88 92 <span type="species:ncbi:10090">mice</span>
###xml 184 188 <span type="species:ncbi:10245">VACV</span>
###xml 262 266 <span type="species:ncbi:10245">VACV</span>
In this study, we have established a mouse model of eczema vaccinatum using a strain of mice that are prone to develop eczematous skin lesions, characterized their immune responses to VACV infection, and showed the importance of NK cells in early suppression of VACV-induced severe eczema vaccinatum-like skin lesions.
###end p 6
###begin title 7
RESULTS AND DISCUSSION
###end title 7
###begin p 8
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 469 477 469 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 698 713 698 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1, B and C</xref>
###xml 915 930 915 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1, B and C</xref>
###xml 1077 1085 1077 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 D</xref>
###xml 1244 1259 1244 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2, A and B</xref>
###xml 85 89 <span type="species:ncbi:10245">VACV</span>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
###xml 250 254 <span type="species:ncbi:10090">mice</span>
###xml 602 606 <span type="species:ncbi:10090">mice</span>
###xml 777 781 <span type="species:ncbi:10090">mice</span>
###xml 795 799 <span type="species:ncbi:10090">mice</span>
###xml 837 841 <span type="species:ncbi:10245">VACV</span>
###xml 981 985 <span type="species:ncbi:10090">mice</span>
###xml 1036 1040 <span type="species:ncbi:10090">mice</span>
###xml 1126 1130 <span type="species:ncbi:10090">mice</span>
###xml 1374 1378 <span type="species:ncbi:10090">mice</span>
###xml 1403 1407 <span type="species:ncbi:10090">mice</span>
###xml 1492 1496 <span type="species:ncbi:10090">mice</span>
###xml 1844 1848 <span type="species:ncbi:10090">mice</span>
We initially focused on establishing experimental conditions in which infection with VACV induces differential clinical outcomes between mice with and without eczematous skin lesions. Skin lesions were induced on the backs of dermatitis-prone NC/Nga mice (10) by epicutaneous treatment of shaved skin with a mite extract and staphylococcal enterotoxin B (SEB), as described previously (11). This treatment induced elevated serum IgE levels and eczematous skin lesions (Fig. 1 A) (11). Skin lesions with maculopapular rash started to appear on the infected site on day 2-3 after infection in eczematous mice and developed into severe skin erosion. The size of the primary lesion peaked at days 7-8 (Fig. 1, B and C), and the lesion began to subside by day 11. Unlike eczematous mice, most normal mice failed to develop skin lesions after VACV infection, and even when developed, their skin lesions were much milder (Fig. 1, B and C). Virus titers in the lesional skin of eczematous mice were 300-10,000 times higher than those of normal mice over an observation period of 14 d (Fig. 1 D). In erosive skin lesions of eczematous mice, epithelial layers were separated from the rest of the skin and more leukocytes infiltrated the diseased dermis (Fig. 2, A and B). Pock-like satellite lesions distant from inoculation sites were rarely seen (only 3 cases out of 230 eczematous mice and 0 out of 187 normal mice). Although weight loss was observed in a small number of both eczematous and normal mice, there was no correlation with skin conditions (unpublished data). Unlike the intradermal infection at eczematous skin lesions, intranasal infection or intradermal infection at distant normal skin sites failed to induce clinical conditions (e.g., weight loss, survival, and size of skin lesions) distinctly different between eczematous and normal mice (unpublished data). Unlike the Western Reserve strain used throughout this study, intradermal infection with the same dose of ACAM2000, the licensed vaccine cloned from Dryvax, caused much milder skin lesions compared with Western Reserve-induced skin lesions (unpublished data).
###end p 8
###begin p 9
###xml 0 75 0 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Induction of erosive primary skin lesions in VACV-infected eczematous mice.</bold>
###xml 602 603 600 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 45 49 <span type="species:ncbi:10245">VACV</span>
###xml 70 74 <span type="species:ncbi:10090">mice</span>
###xml 161 165 <span type="species:ncbi:10090">mice</span>
###xml 229 233 <span type="species:ncbi:10245">VACV</span>
###xml 281 285 <span type="species:ncbi:10090">mice</span>
###xml 400 404 <span type="species:ncbi:10090">mice</span>
###xml 543 547 <span type="species:ncbi:10090">mice</span>
###xml 608 612 <span type="species:ncbi:10090">mice</span>
###xml 788 792 <span type="species:ncbi:10090">mice</span>
Induction of erosive primary skin lesions in VACV-infected eczematous mice. (A) Eczematous skin lesions were induced by repeated Der f/SEB (D/B) treatments, and mice with a clinical score of >/=8 were infected intradermally with VACV (eczematous group). A cohort (normal group) of mice with healthy skin was also infected at the same anatomical site. (B) Typical eczematous (right) and normal (left) mice are shown on day 6 after infection. (C) The size of erosive skin lesions. Shown is a representative of at least 15 experiments using 4-10 mice in each group. (D) Virus titers in the infected skin (n = 7 mice per group). Shown are results representative of four independent experiments. Data represent means and SEM values. *, P < 0.05; **, P < 0.01; and ***, P < 0.001 versus normal mice. ND, not detected.
###end p 9
###begin p 10
###xml 0 58 0 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Histology of skin lesions before and after VACV infection.</bold>
###xml 203 204 203 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 209 210 209 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 221 222 221 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 394 395 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 523 524 523 524 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 43 47 <span type="species:ncbi:10245">VACV</span>
###xml 142 146 <span type="species:ncbi:10090">mice</span>
###xml 559 563 <span type="species:ncbi:10090">mice</span>
Histology of skin lesions before and after VACV infection. (A) Hematoxylin and eosin-stained skin tissues are shown for normal and eczematous mice before and 7 d after virus infection. Bar, 1 mm. (B) CD4+, CD8+, and Mac-1+ cells were stained by immunohistochemistry and mast cells were stained with toluidine blue. Data represent means and SEM values of cell numbers per high-power field (HPF; n = 8 each group). (C) Immunohistochemical staining of NK cells with anti-Ly49G2 (clone 4D11) mAb. Bar, 0.1 mm. (D) Ly49G2 (4D11)+ NK cells were enumerated with six mice per cohort. Shown are results representative of six independent experiments. Data represent means and SEM. *, P < 0.05; **, P < 0.01; and ***, P < 0.001. NS, not significant.
###end p 10
###begin p 11
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 203 218 203 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2, C and D</xref>
###xml 337 345 337 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 A</xref>
###xml 577 585 573 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 B</xref>
###xml 197 201 <span type="species:ncbi:10090">mice</span>
###xml 299 303 <span type="species:ncbi:10090">mice</span>
###xml 571 575 <span type="species:ncbi:10090">mice</span>
Because of the importance of NK cells in rapid antiviral defense (12, 13), we quantified their numbers and activities. NK cells were more abundant in primary skin lesions in eczematous than normal mice (Fig. 2, C and D). Importantly, NK cell cytotoxic activity in the spleen was lower in eczematous mice on days 2 and 3 after infection (Fig. 3 A). We measured expression of molecules involved in NK killing activity by flow cytometry and found that the proportions of splenic NK cells expressing granzyme B, perforin, and IFN-gamma were significantly lower in eczematous mice (Fig. 3 B).
###end p 11
###begin p 12
###xml 0 114 0 114 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Reduced NK cell activity was critical for the development of VACV-induced erosive skin lesions in eczematous mice.</bold>
###xml 507 508 507 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 514 515 514 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1549 1550 1502 1503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 61 65 <span type="species:ncbi:10245">VACV</span>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
###xml 427 431 <span type="species:ncbi:10090">mice</span>
###xml 466 470 <span type="species:ncbi:10090">mice</span>
###xml 752 756 <span type="species:ncbi:10090">mice</span>
###xml 821 825 <span type="species:ncbi:10090">mice</span>
###xml 876 880 <span type="species:ncbi:10090">mice</span>
###xml 944 948 <span type="species:ncbi:10090">mice</span>
###xml 1021 1025 <span type="species:ncbi:10090">mice</span>
###xml 1153 1157 <span type="species:ncbi:10090">mice</span>
###xml 1332 1336 <span type="species:ncbi:10090">mice</span>
###xml 1432 1436 <span type="species:ncbi:10090">mice</span>
###xml 1557 1561 <span type="species:ncbi:10090">mice</span>
Reduced NK cell activity was critical for the development of VACV-induced erosive skin lesions in eczematous mice. (A) NK cell cytotoxic activity of splenocytes on day 2 after infection was measured using YAC-1 cells as target cells at the indicated effector-to-target ratios. Shown are results representative of 5 independent experiments. Data represent means and SEM values. *, P < 0.05; and ***, P < 0.001 versus uninfected mice. ###, P < 0.001 versus eczematous mice. (B) Flow cytometric analysis of CD3- NK1.1+ NK cells expressing granzyme B, perforin, or IFN-gamma in spleens. Shown are results representative of 8 independent experiments. *, P < 0.05; **, P < 0.01; and ***, P < 0.001. (C) Virus titers in spleens from alphaAGM1- or NRS-treated mice. (D) Sizes of primary skin lesions in alphaAGM1- or NRS-treated mice. *, comparison between alphaAGM1- and NRS-treated mice; #, comparison between alphaAGM1-treated normal and eczematous mice; and section sign, comparison between NRS-treated normal and eczematous mice (one, two, and three symbols indicate P < 0.05, 0.01, and 0.001, respectively. (E) Virus infection in alphaAGM1-treated normal mice induced erythematous papules at the inoculation site (indicated by the arrow; top) and satellite lesions. Satellite lesions were also induced in alphaAGM1-treated eczematous mice (indicated by arrowheads). Satellite lesions in both normal/alphaAGM1 and eczematous/alphaAGM1 mice were confirmed to contain live virus. Shown in C-E are representative results of three independent experiments (n = 4-8 mice per group). (F) Adoptive transfer of cultured NK cells. Sizes of primary skin lesions are shown. The inset shows the purity of transferred NK cells as analyzed by flow cytometry. Shown are results representative of three independent experiments. Data in A and C-F represent means and SEM values; data in B represent means and SD values.
###end p 12
###begin p 13
###xml 256 257 256 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 686 687 682 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 30 34 <span type="species:ncbi:10245">VACV</span>
###xml 179 183 <span type="species:ncbi:10090">mice</span>
###xml 525 529 <span type="species:ncbi:10245">VACV</span>
###xml 574 578 <span type="species:ncbi:10090">mice</span>
###xml 680 684 <span type="species:ncbi:10090">mice</span>
IgM and IgG responses against VACV were similar between the eczematous and normal cohorts (). Consistent with this, IL-4 mRNA levels in lymph nodes were not reduced in eczematous mice for the initial 7 d after infection (Fig. S1 B). Killing activity of CD8+ T cells and their expression of granzyme B, perforin, and IFN-gamma in day 7 spleens did not show differences between the two cohorts (unpublished data). These results suggest that adaptive immunity does not play a major role in causing differential skin outcomes of VACV infection between the eczematous and normal mice, although these arms of immunity are critical in the control of virus infection in vaccinia-infected mice (8).
###end p 13
###begin p 14
###xml 351 352 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 777 785 761 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 C</xref>
###xml 1178 1186 1146 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 E</xref>
###xml 1301 1309 1269 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 D</xref>
###xml 1432 1440 1400 1408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 D</xref>
###xml 1514 1516 1478 1480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">14</xref>
###xml 128 132 <span type="species:ncbi:10090">mice</span>
###xml 183 187 <span type="species:ncbi:10090">mice</span>
###xml 260 266 <span type="species:ncbi:9986">rabbit</span>
###xml 490 494 <span type="species:ncbi:10090">mice</span>
###xml 553 557 <span type="species:ncbi:10090">mice</span>
###xml 704 708 <span type="species:ncbi:10090">mice</span>
###xml 840 844 <span type="species:ncbi:10090">mice</span>
###xml 878 882 <span type="species:ncbi:10090">mice</span>
###xml 910 914 <span type="species:ncbi:10090">mice</span>
###xml 1035 1039 <span type="species:ncbi:10090">mice</span>
###xml 1136 1140 <span type="species:ncbi:10090">mice</span>
###xml 1200 1204 <span type="species:ncbi:10090">mice</span>
###xml 1295 1299 <span type="species:ncbi:10090">mice</span>
###xml 1360 1364 <span type="species:ncbi:10090">mice</span>
###xml 1426 1430 <span type="species:ncbi:10090">mice</span>
The role of NK cells in this eczema vaccinatum model was assessed by depletion studies. First, dermatitis was induced in NC/Nga mice. 1 d before infection and on d 3 after infection, mice were intravenously injected with anti-asialo GM1 (alphaAGM1) or control rabbit serum (NRS). Treatment with alphaAGM1 serum drastically reduced the numbers of NK1.1+ cells in the spleens (73-89% reduced as evaluated by flow cytometry) and suppressed NK cell activity in spleens in day 3-infected normal mice (normal/alphaAGM1 group) compared with NRS-treated normal mice (normal/NRS group; ). In contrast, alphaAGM1 treatment did not significantly reduce the already low NK cell activity in day 3-infected eczematous mice. Substantially higher virus titers were observed in lesional skins (Fig. 3 C) and lungs (not depicted) of alphaAGM1-treated normal mice than those of NRS-treated normal mice. Importantly, 14 out of 16 mice in the normal/alphaAGM1 group exhibited erythematous papules at the inoculation site by day 6, whereas only 1 out of 13 mice in the normal/NRS group developed such a lesion. Some normal/alphaAGM1 and eczematous/alphaAGM1 mice developed satellite lesions as well (Fig. 3 E). Eczematous mice developed larger erosive skin lesions at the site of virus inoculation than noneczematous mice (Fig. 3 D). These primary lesions in NK-depleted eczematous mice were significantly larger than lesions in control eczematous mice (Fig. 3 D). As alphaAGM1 treatment might affect other cell types besides NK cells (14), we performed a second experiment in which we depleted NK cells by administering anti-NK1.1 mAb. Results were similar to those with alphaAGM1 ().
###end p 14
###begin p 15
###xml 284 285 284 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 291 292 291 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 305 313 305 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 F</xref>
###xml 509 517 509 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 F</xref>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
###xml 378 382 <span type="species:ncbi:10090">mice</span>
###xml 608 612 <span type="species:ncbi:10090">mice</span>
###xml 769 773 <span type="species:ncbi:10090">mice</span>
###xml 790 794 <span type="species:ncbi:10245">VACV</span>
###xml 866 871 <span type="species:ncbi:10090">mouse</span>
To complement the NK depletion experiments, we performed adoptive transfer of NK cells to determine whether activated NK cells could rescue NC/Nga mice from eczema vaccinatum. NK cells were obtained by culturing splenocytes in IL-15 for 4 d. The cultured cells, composed of a >95% CD3- NK1.1+ population (Fig. 3 F, inset), were intravenously transferred to eczematous or normal mice. Transfer of NK cells either totally suppressed the development of erosive skin lesions or greatly reduced skin lesion sizes (Fig. 3 F). The activated NK cells also delayed the kinetics of lesion development in the subset of mice that eventually developed erosive skin lesions. Therefore, the NK depletion and transfer experiments demonstrate a critical role for NK cells in protecting mice from developing VACV-induced erosive skin lesions and satellite skin lesions in this NC/Nga mouse model of eczema vaccinatum.
###end p 15
###begin p 16
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">15</xref>
###xml 415 423 412 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 614 622 611 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 737 745 734 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 B</xref>
###xml 204 208 <span type="species:ncbi:10090">mice</span>
###xml 511 515 <span type="species:ncbi:10090">mice</span>
###xml 608 612 <span type="species:ncbi:10090">mice</span>
###xml 731 735 <span type="species:ncbi:10090">mice</span>
###xml 916 920 <span type="species:ncbi:10090">mice</span>
NK cell function is under the control of various cytokines, including IL-6 and IL-10, which each inhibit NK cell activity. The proinflammatory cytokine IL-17 is produced by Th17 cells (15). In eczematous mice, real-time PCR analysis of splenocytes showed increased mRNA expression of IL-17A and the cytokines involved in Th17 development (IL-6, TGF-beta, IL-21, and IL-23) and effector functions (IL-21 and IL-22) (Fig. 4 A). IL-17A and IL-6 mRNAs were also increased in lesional skins of uninfected eczematous mice, whereas IL-17A, IL-6, and IL-23 mRNAs were increased in draining lymph nodes of eczematous mice (Fig. 4 A). Consistent with these mRNA results, lymph nodes contained an increased number of Th17 cells in eczematous mice (Fig. 4 B). In contrast with Th17-related cytokines, surface expression of NK cell receptors such as NKG2D, NKG2A/C/E, Ly49A/D, and Ly49I/G was comparable in eczematous and normal mice (unpublished data).
###end p 16
###begin p 17
###xml 0 66 0 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Role of IL-17A in reduced NK cell cytotoxicity in eczematous mice.</bold>
###xml 349 350 349 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 411 412 411 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 426 427 426 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 430 431 430 431 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 436 437 436 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
###xml 278 282 <span type="species:ncbi:10090">mice</span>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 610 614 <span type="species:ncbi:10090">mice</span>
###xml 904 908 <span type="species:ncbi:10090">mice</span>
###xml 1131 1135 <span type="species:ncbi:10090">Mice</span>
###xml 1187 1191 <span type="species:ncbi:10245">VACV</span>
###xml 1296 1300 <span type="species:ncbi:10245">VACV</span>
###xml 1588 1591 <span type="species:ncbi:10116">rat</span>
###xml 1607 1611 <span type="species:ncbi:10090">mice</span>
###xml 1667 1671 <span type="species:ncbi:10090">mice</span>
Role of IL-17A in reduced NK cell cytotoxicity in eczematous mice. (A) mRNA expression of IL-17A and Th17-related cytokines was analyzed by real-time PCR (spleen) or semiquantitative RT-PCR analysis (skin and draining lymph node). Values were normalized against those of normal mice. Shown are results representative of two independent experiments (n = 4-6 mice). *, P < 0.05; and **, P < 0.01 by the Student's t test. (B) CD3+CD4+IL-17+ Th17 cells were enumerated in draining lymph nodes. (C) The onset of skin lesion development was delayed (left) and the size of primary skin lesions was smaller (right) in mice treated with anti-IL-17 mAb. **, P < 0.01 versus control. (D) NK cells in spleens and lesional skin were enumerated by flow cytometry and immunohistochemistry, respectively. (E) Splenic NK cells expressing granzyme B (GzmB), perforin (Pfn), or IFN-gamma were analyzed by flow cytometry in mice treated with anti-IL-17 or control mAb day 2 after infection. (F) Virus titers were measured on day 7. Shown are representative results from three independent experiments. *, P < 0.05; and **, P < 0.01 versus control. (G) Mice were NK-depleted by alphaAGM1 injection 1 d before VACV infection. Anti-IL-17 antibody was also intraperitoneally injected 2 h after alphaAGM1 injection. After VACV infection, anti-IL-17 was injected on days 1 and 3, and alphaAGM1 was injected on days 2 and 5. Skin lesion development was observed and lesion size was measured for 6 d. The result is a representative of two independent experiments. *, P < 0.05; **, P < 0.01; and ***, P < 0.001 versus rat IgG2a-injected mice. #, P < 0.05 versus anti-IL-17 treated, NK-nondepleted mice. Data represent means and SEM values.
###end p 17
###begin p 18
###xml 215 223 215 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 C</xref>
###xml 365 373 365 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 D</xref>
###xml 493 501 489 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 E</xref>
###xml 617 625 613 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 F</xref>
###xml 774 782 766 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 G</xref>
###xml 1108 1114 1100 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5</xref>
###xml 1185 1191 1177 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5</xref>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
###xml 487 491 <span type="species:ncbi:10090">mice</span>
###xml 611 615 <span type="species:ncbi:10090">mice</span>
###xml 1427 1431 <span type="species:ncbi:10090">mice</span>
Neutralization of IL-17A in eczematous mice with anti-IL-17 antibody caused a delay in the onset of skin lesions after virus infection, and the lesion size was significantly smaller on days 2 and 3 after infection (Fig. 4 C). Although the number and the percentage of NK cells in the spleen and at the lesion site were not changed by anti-IL-17 antibody treatment (Fig. 4 D), the proportions of NK cells expressing granzyme B, perforin, and IFN-gamma were increased in IL-17-neutralized mice (Fig. 4 E). Consistent with these changes, viral loads in the spleen and lesional skin were lower in IL-17-neutralized mice (Fig. 4 F). Furthermore, when the NK cells were depleted by alphaAGM1 antibody, the effect of anti-IL-17 antibody treatment on the incidence and lesion size (Fig. 4 G) and viral titers () was almost abrogated, indicating that effects of IL-17 neutralization are exerted through the regulation of NK cells. Consistent with these in vivo findings, the expression of killing effector molecules in cultured splenic NK cells was reduced by IL-17A in a dose-dependent manner (), but not by IL-17F (Fig. 5). IL-17A reduced the expression of killing effectors induced by IL-4 (Fig. 5), IL-2, IL-12, IL-15, or IL-18 (). The survival of these NK cells was not affected by IL-17A or IL-17F (unpublished data). These results collectively suggest that IL-17A plays a critical role in lowering NK cell activity in eczematous mice.
###end p 18
###begin p 19
###xml 0 60 0 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17A but not IL-17F reduces NK cell cytotoxicity in vitro.</bold>
IL-17A but not IL-17F reduces NK cell cytotoxicity in vitro. Splenic NK cells were incubated with the indicated cytokines for 48 h before flow cytometric analysis of NK cells expressing granzyme B, perforin, or IFN-gamma. Shown are results representative of two independent experiments. Data represent means and SEM values. **, P < 0.01; and ***, P < 0.001 versus IL-4 by one-way analysis of variance.
###end p 19
###begin p 20
###xml 68 70 68 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">16</xref>
###xml 150 154 <span type="species:ncbi:10245">VACV</span>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
###xml 257 261 <span type="species:ncbi:10090">mice</span>
###xml 423 427 <span type="species:ncbi:10090">mice</span>
IL-15 is required for the proliferation and activation of NK cells (16). Antibody-mediated neutralization of IL-15 caused more severe skin lesions in VACV-infected normal mice compared with the control cohort (). However, IL-15 neutralization in eczematous mice did not induce significant differences in skin lesion development. Although the mRNA level of IL-15 is not significantly different between normal and eczematous mice (unpublished data), the results of IL-15 neutralization further confirm that NK cell activity is critical for early protection from skin lesion development.
###end p 20
###begin p 21
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
###xml 440 442 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
###xml 476 477 476 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 479 480 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 602 604 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">19</xref>
###xml 606 608 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 703 705 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">21</xref>
###xml 706 708 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">23</xref>
###xml 1020 1022 1017 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">24</xref>
###xml 1322 1324 1319 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">25</xref>
###xml 1326 1328 1323 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
###xml 1468 1470 1465 1467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 1472 1474 1469 1471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
###xml 1476 1478 1473 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">27</xref>
###xml 76 81 <span type="species:ncbi:9606">human</span>
###xml 122 126 <span type="species:ncbi:10090">mice</span>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
###xml 386 392 <span type="species:ncbi:9606">humans</span>
###xml 801 805 <span type="species:ncbi:10090">mice</span>
###xml 1127 1131 <span type="species:ncbi:10245">VACV</span>
###xml 1308 1312 <span type="species:ncbi:10245">VACV</span>
###xml 1316 1320 <span type="species:ncbi:10090">mice</span>
###xml 1396 1402 <span type="species:ncbi:9606">humans</span>
Our NC/Nga infection model does not exhibit all of the expected features of human eczema vaccinatum. For instance, NC/Nga mice with eczematous skin lesions exhibited functional but not numerical defects in NK cells, unlike atopic dermatitis patients, who have defects in both number and function (17, 18). Nevertheless, this model exhibits key features of atopic dermatitis observed in humans, including defective NK cell killing activity (17, 18) and high IL-17A expression (5, 6). IL-6 and TGF-beta are required for induction of Th17 cells, and IL-23 is required for the establishment of Th17 cells (19, 20). IL-21 is produced by Th17 cells and exerts critical functions in Th17 cell differentiation (21-23). Th17 cells were more abundant and the Th17-related cytokines were increased in eczematous mice, suggesting that Th17 cells may be involved in reducing NK cell killing activity. The NK cell-suppressive function of IL-17A observed in our in vitro and in vivo studies was consistent with an earlier IL-17 study (24), although it is possible that the increased IL-17A and Th17-related cytokines might also contribute to VACV-induced inflammation via the enhanced immunopathology. Our results also support the conclusion that NK cells are important in controlling early local and systemic spreading of VACV in mice (25, 26). Although atopic dermatitis is still only partially understood in humans, there are strong indications that NK cell defects are involved (17, 18, 27). Our data now show that critical failures in NK cell-mediated immunity allow for disastrous early spread of vaccinia after cutaneous infection, and these NK cell defects are related to the immunosuppressive effects of IL-17A.
###end p 21
###begin title 22
MATRIALS AND METHODS
###end title 22
###begin title 23

###end title 23
###begin title 24
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse infection.
###end title 24
###begin p 25
###xml 13 15 13 15 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 231 255 231 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Dermatophagoides farinae</italic>
###xml 507 508 505 506 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 7 11 <span type="species:ncbi:10090">mice</span>
###xml 131 135 <span type="species:ncbi:10090">mice</span>
###xml 231 255 <span type="species:ncbi:6954">Dermatophagoides farinae</span>
###xml 418 422 <span type="species:ncbi:10090">Mice</span>
###xml 529 533 <span type="species:ncbi:10245">VACV</span>
###xml 637 641 <span type="species:ncbi:10090">mice</span>
###xml 1184 1189 <span type="species:ncbi:10090">mouse</span>
NC/Nga mice (10) were used in all animal experiments. Eczematous skin lesions were induced as described previously (11). In brief, mice were shaved on the back and dermatitis was induced by two rounds of a week-long treatment with Dermatophagoides farinae extract (Der f; Greer Laboratories) and SEB (Sigma-Aldrich). During this treatment, their back was occluded with a bandage, which was removed the following week. Mice with a clinical score of >/=8 (eczematous group) were intradermally injected with 106 PFU per 3 microl of VACV (Western Reserve strain) at the center of skin lesions. A cohort (normal group) of age and sex-matched mice with healthy skin was also infected at the same anatomical site. Clinical scores of eczematous skin lesions are based on severity (0, no signs; 1, mild; 2, intermediate; 3, severe) of four signs (redness, bleeding, eruption, and scaling). Scoring was performed in a blind manner. The virus was prepared by repeated (three times) freeze-thaw cycles of infected HeLa cells in DMEM/1% FCS followed by centrifugation. Uninfected HeLa cell extract was used as control. Virus titers were measured by plaque-forming assays on Vero cells. All of the mouse experiments were approved by an Institutional Review Board of the La Jolla Institute for Allergy and Immunology.
###end p 25
###begin title 26
Histology.
###end title 26
###begin p 27
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 12 13 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 28 29 28 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 70 71 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
CD4+ and CD8+ T cells, Mac-1+ monocytes/macrophages, and Ly49G2 (4D11)+ NK cells were detected by immunochemical staining. Mast cells were stained by toluidine blue, and eosinophils and neutrophils were detected by hematoxylin and eosin or Congo red staining.
###end p 27
###begin title 28
NK cell assay.
###end title 28
###begin p 29
NK cell activity was measured using YAC-1 cells as target cells, with effector-to-target ratios (12.5:1, 25:1, and 50:1) in spleen cells isolated on day 2 or 3 after infection.
###end p 29
###begin title 30
NK cell cultures.
###end title 30
###begin p 31
###xml 24 28 <span type="species:ncbi:10090">mice</span>
###xml 101 106 <span type="species:ncbi:10090">mouse</span>
Splenocytes from NC/Nga mice were negatively selected by MACS beads (Miltenyi Biotec) or the EasySep mouse NK cell enrichment kit (StemCell Technologies Inc.). These NK-enriched cells were cultured in RPMI 1640 with 10% FBS containing 500 ng/ml IL-15 for 4 d. The purity of NK cells was checked by flow cytometry after staining with anti-NK1.1 and anti-CD3 antibodies before the use for adoptive transfer. For in vitro NK cell assays, purified splenic NK cells or whole splenocytes were cultured in RPMI 1640 with 10% FBS containing 20 ng/ml IL-4 and/or 50 ng/ml IL-17A or IL-17F with or without 2 microg/ml anti-IL-17RA for 2 d, followed by flow cytometry.
###end p 31
###begin title 32
Flow cytometry.
###end title 32
###begin p 33
Single-cell suspensions of splenocytes or lymph node cells were surface stained with anti-NK1.1 and CD3. The cells were then fixed, permeabilized, and stained with anti-granzyme A, -granzyme B, -perforin, or -IFN-gamma. Data were acquired with a FACSCalibur (BD) and analyzed using FlowJo software (Tree Star, Inc.).
###end p 33
###begin title 34
RT-PCR.
###end title 34
###begin p 35
###xml 169 172 169 172 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">zol</sc>
Skin tissues were taken from infection sites or erosive areas by punch biopsy, and axillary lymph nodes and spleens were also isolated. Total RNAs were isolated with TRIzol reagent (Invitrogen) and used as a template to prepare cDNAs. PCR products were analyzed by agarose gel elctrophoresis. Quantitative PCR was performed using a LightCycler 480 (Roche).
###end p 35
###begin title 36
Statistical analysis.
###end title 36
###begin p 37
Statistical analysis in each independent experiment was performed with an unpaired, two-way analysis of variance using Prism software (GraphPad Software, Inc.), otherwise noted. P < 0.05 was considered statistically significant.
###end p 37
###begin title 38
Online supplemental material.
###end title 38
###begin p 39
###xml 181 185 <span type="species:ncbi:10090">mice</span>
###xml 370 374 <span type="species:ncbi:10090">mice</span>
Fig. S1 shows antibody responses. Fig. S2 depicts alphaAGM1 effects on NK cells. Fig. S3 shows anti-NK1.1 effects. Fig. S4 depicts viral titers in anti-IL-17- and alphaAGM1-treated mice. Fig. S5 shows in vitro effects of IL-17A on NK cell mediators. Fig. S6 depicts the effects of various cytokines on NK cell mediators. Fig. S7 shows skin lesions in anti-IL-15-treated mice. Online supplemental material is available at .
###end p 39
###begin title 40
Supplementary Material
###end title 40
###begin title 41
[Supplemental Material Index]
###end title 41
###begin p 42
The authors thank M. McCausland for excellent technical assistance, and Drs. W.M. Yokoyama and L.L. Lanier for helpful discussion.
###end p 42
###begin p 43
This study was supported in part by Atopic Dermatitis and Vaccinia Network National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases contract N01 AI40030 to T. Kawakami, and NIH grants AI63107 and AI77953 to S. Crotty. This study is publication no. 1071 from the La Jolla Institute for Allergy and Immunology.
###end p 43
###begin p 44
The authors declare no competing financial interests.
###end p 44
###begin article-title 45
New insights into atopic dermatitis.
###end article-title 45
###begin article-title 46
###xml 0 8 <span type="species:ncbi:10255">Smallpox</span>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Smallpox vaccination: Risk considerations for patients with atopic dermatitis.
###end article-title 46
###begin article-title 47
Atopic dermatitis.
###end article-title 47
###begin article-title 48
New insights into the complex gene-environment interactions evolving into atopic dermatitis.
###end article-title 48
###begin article-title 49
Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions.
###end article-title 49
###begin article-title 50
Possible pathogenic role of Th17 cells for atopic dermatitis.
###end article-title 50
###begin article-title 51
Scratching the surface: towards understanding the pathogenesis of atopic dermatitis.
###end article-title 51
###begin article-title 52
###xml 44 52 <span type="species:ncbi:10255">smallpox</span>
Immunity and immunological memory following smallpox vaccination.
###end article-title 52
###begin article-title 53
Viral infections in atopic dermatitis: pathogenic aspects and clinical management.
###end article-title 53
###begin article-title 54
###xml 85 89 <span type="species:ncbi:10090">mice</span>
Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice.
###end article-title 54
###begin article-title 55
###xml 12 17 <span type="species:ncbi:10090">mouse</span>
An improved mouse model of atopic dermatitis and suppression of skin lesions by an inhibitor of tec family kinases.
###end article-title 55
###begin article-title 56
Evolutionary struggles between NK cells and viruses.
###end article-title 56
###begin article-title 57
Keeping NK cells in highly regulated antiviral warfare.
###end article-title 57
###begin article-title 58
###xml 10 16 <span type="species:ncbi:9986">rabbit</span>
Effect of rabbit anti-asialo GM1 treatment in vivo or with anti-asialo GM1 plus complement in vitro on cytotoxic T cell activities.
###end article-title 58
###begin article-title 59
IL-17 family cytokines and the expanding diversity of effector T cell lineages.
###end article-title 59
###begin article-title 60
###xml 50 55 <span type="species:ncbi:9606">human</span>
Interleukin-2, interleukin-15, and their roles in human natural killer cells.
###end article-title 60
###begin article-title 61
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Modulation of natural killer cell activity in patients with atopic dermatitis.
###end article-title 61
###begin article-title 62
Natural-killer-cell activity in atopic dermatitis.
###end article-title 62
###begin article-title 63
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.
###end article-title 63
###begin article-title 64
###xml 60 61 60 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
Transforming growth factor-beta induces development of the TH17 lineage.
###end article-title 64
###begin article-title 65
###xml 66 67 66 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells.
###end article-title 65
###begin article-title 66
Essential autocrine regulation by IL-21 in the generation of inflammatory T cells.
###end article-title 66
###begin article-title 67
###xml 15 16 15 16 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways.
###end article-title 67
###begin article-title 68
###xml 48 62 <span type="species:ncbi:10245">vaccinia virus</span>
Interleukin 17 modulates the immune response to vaccinia virus infection.
###end article-title 68
###begin article-title 69
Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo.
###end article-title 69
###begin article-title 70
Specific and nonspecific NK cell activation during virus infection.
###end article-title 70
###begin article-title 71
###xml 23 24 15 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 112 120 <span type="species:ncbi:9606">patients</span>
NK cells and gammadelta+ T cells are phenotypically and functionally defective due to preferential apoptosis in patients with atopic dermatitis.
###end article-title 71

